Furthermore, the high-risk genetic landscape observed in GATA-3 PTCL, including 17p/TP53 deletions and mutations, collectively observed in ≈50% of GATA-3 PTCL, may explain, at least in part, the chemotherapy resistance and dismal outcomes observed in this subgroup. This evidence concerns the gene TP53 and mature T-cell and NK-cell non-Hodgkin lymphoma.